Abdus S. Wahed

Abdus S. Wahed

Auto-generated profile, based on publicly available information

Abdus S. Wahed

Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2016 in JAMA
Verified
Journal Article
Open access
PDF file
JJJohn M. M. Jakicic
John M. M. Jakicic
KDKelliann K. Davis
Kelliann K. Davis
RRRenee J. Rogers
Renee J. Rogers
WKWendy C. King
Wendy C. King
MMMarsha D. Marcus
Marsha D. Marcus
SBSteven H. Belle
Steven H. Belle
Overweight and obesity have high prevalence1 and are associated with numerous health conditions.2 Interventions emphasizing both diet and physical activity are effective for weight loss, resulting in 6-month weight loss of 8% to 10% of initial weight.3 However, challenges remain to sustaining weight loss long-term.3

1 March 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JPJang-June Park
Jang-June Park
DWDavid K. Wong
David K. Wong
AWAbdus S. Wahed
Abdus S. Wahed
WLWilliam M. Lee
William M. Lee
JFJordan J. Feld
Jordan J. Feld
DKDavid Kleiner
David Kleiner
Background & Aims T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). Methods We enrolled 200 adults with CHB who participated in the National Institutes of Health−supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. Results Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3+CD127− regulatory T cells and CD4+ T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)+ than HBeAg− patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg+ than HBeAg− patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. Conclusions HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell−based immune signatures for clinical phenotypes. These findings suggest additional T-cell−independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation.

9 February 2009 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
OLO L Lopez
O L Lopez
JBJ T Becker
J T Becker
AWA S Wahed
A S Wahed
JSJ Saxton
J Saxton
RSR A Sweet
R A Sweet
SDSteven Trent DeKosky
Steven Trent DeKosky
Background: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission. Methods: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (45.0%) used only ChEIs, and 416 (40.1%) used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications). Results: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death. Conclusions: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.

18 July 2012 in JAMA
Verified
Journal Article
Open access
PDF file
MFMichael W. Fried
Michael W. Fried
VNVictor J. Navarro
Victor J. Navarro
NANezam Afdhal
Nezam Afdhal
SBSteven H. Belle
Steven H. Belle
AWAbdus S. Wahed
Abdus S. Wahed
FNFor The Silymarin In Nash
For The Silymarin In Nash
Chronic hepatitis C virus (HCV) infection affects almost 3% of the global population and may lead to cirrhosis, hepatic failure, and hepatocellular carcinoma.1 Sustained virological response can be achieved in patients treated with peginterferon and ribavirin, often combined with an HCV protease inhibitor.2-4 Nevertheless, a large proportion of patients do not respond to these therapies, and many others cannot be treated because of medical comorbidities.5 Thus, alternative medications with disease-modifying activity may be of benefit.

22 December 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
HCHari S. Conjeevaram
Hari S. Conjeevaram
DKDavid E. Kleiner
David E. Kleiner
JEJay E. Everhart
Jay E. Everhart
JHJay H. Hoofnagle
Jay H. Hoofnagle
SZSteven Zacks
Steven Zacks
AWAbdus S. Wahed
Abdus S. Wahed
Hepatic steatosis is common in chronic hepatitis C and has been linked to concurrent obesity, insulin resistance, diabetes, disease severity, and poor response to therapy. Racial differences in rates of obesity and diabetes may contribute to racial differences in hepatic steatosis and treatment response. The aim of the present study was to compare hepatic steatosis and its associations between African American (AA) and Caucasian American (CA) patients with chronic hepatitis C, genotype 1, participating in a prospective study of peginterferon and ribavirin therapy. Liver biopsy results were available from 194 AA patients and 205 CA patients. The 2 groups were compared for anthropometric, clinical, and biochemical features and insulin resistance estimated by the homeostasis model assessment index (HOMA-IR). Sixty-one percent of the AA patients and 65% of the CA patients had hepatic steatosis ( P = 0.38). In univariable analysis, steatosis was associated with HOMA-IR, body mass index, waist circumference, serum triglycerides, aminotransferase level, and histological scores for inflammation and fibrosis. After adjusting for these features, AA patients had a lower risk of steatosis than did CA patients (OR 0.54, 95% CI 0.32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028). Conclusion : After adjusting for the higher prevalence of features associated with hepatic steatosis, AA patients had a lower prevalence of hepatic steatosis than did CA patients with chronic hepatitis C, genotype 1. Insulin resistance but not steatosis was independently associated with lower sustained virological response. (Hepatology 2006;45:80–87.)

1 April 2010 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RHRoy Hawke
Roy Hawke
SSSarah J. Schrieber
Sarah J. Schrieber
TSTedi A. Soule
Tedi A. Soule
ZWZhiming Wen
Zhiming Wen
PSPhilip C. Smith
Philip C. Smith
TGThe SyNCH Trial Group
The SyNCH Trial Group